Lazard Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.1M | Buy |
17,004
+6,166
| +57% | +$4.72M | 0.02% | 390 |
|
|
2025
Q4 | $8.37M | Buy |
10,838
+458
| +4% | +$311K | 0.01% | 440 |
|
|
2025
Q3 | $5.84M | Buy |
10,380
+10,129
| +4,035% | +$5.73M | 0.01% | 539 |
|
|
2025
Q2 | $131K | Sell |
251
-16,712
| -99% | -$9.33M | ﹤0.01% | 1801 |
|
|
2025
Q1 | $10.8M | Sell |
16,963
-2,949
| -15% | -$2.03M | 0.02% | 472 |
|
|
2024
Q4 | $14.2M | Buy |
19,912
+3,696
| +23% | +$3.1M | 0.02% | 404 |
|
|
2024
Q3 | $17M | Sell |
16,216
-234
| -1% | -$260K | 0.02% | 366 |
|
|
2024
Q2 | $17.3M | Buy |
16,450
+141
| +0.9% | +$137K | 0.02% | 407 |
|
|
2024
Q1 | $15.7M | Buy |
16,309
+5,627
| +53% | +$5.35M | 0.02% | 432 |
|
|
2023
Q4 | $9.38M | Sell |
10,682
-374
| -3% | -$308K | 0.01% | 563 |
|
|
2023
Q3 | $9.1M | Sell |
11,056
-100
| -0.9% | -$78.6K | 0.01% | 580 |
|
|
2023
Q2 | $8.02M | Sell |
11,156
-3,197
| -22% | -$2.46M | 0.01% | 602 |
|
|
2023
Q1 | $11.8M | Buy |
14,353
+177
| +1% | +$133K | 0.02% | 549 |
|
|
2022
Q4 | $10.2M | Buy |
14,176
+1,031
| +8% | +$761K | 0.01% | 570 |
|
|
2022
Q3 | $9.05M | Buy |
13,145
+584
| +5% | +$368K | 0.01% | 595 |
|
|
2022
Q2 | $7.42M | Buy |
12,561
+2,995
| +31% | +$1.95M | 0.01% | 647 |
|
|
2022
Q1 | $6.68M | Buy |
9,566
+4,007
| +72% | +$2.54M | 0.01% | 708 |
|
|
2021
Q4 | $3.51M | Buy |
5,559
+80
| +1% | +$49.2K | ﹤0.01% | 841 |
|
|
2021
Q3 | $3.31M | Buy |
5,479
+4,458
| +437% | +$2.77M | ﹤0.01% | 838 |
|
|
2021
Q2 | $570K | Sell |
1,021
-2,164
| -68% | -$1.1M | ﹤0.01% | 1040 |
|
|
2021
Q1 | $1.51M | Sell |
3,185
-9,313
| -75% | -$4.53M | ﹤0.01% | 833 |
|
|
2020
Q4 | $6.04M | Sell |
12,498
-4,676
| -27% | -$2.52M | 0.01% | 629 |
|
|
2020
Q3 | $9.61M | Sell |
17,174
-1,519
| -8% | -$921K | 0.01% | 505 |
|
|
2020
Q2 | $11.7M | Buy |
18,693
+12,795
| +217% | +$7.26M | 0.02% | 455 |
|
|
2020
Q1 | $2.88M | Sell |
5,898
-954
| -14% | -$394K | 0.01% | 618 |
|
|
2019
Q4 | $2.57M | Buy |
6,852
+160
| +2% | +$53.8K | ﹤0.01% | 638 |
|
|
2019
Q3 | $1.86M | Buy |
6,692
+4,634
| +225% | +$1.37M | ﹤0.01% | 680 |
|
|
2019
Q2 | $644K | Sell |
2,058
-6,688
| -76% | -$2.23M | ﹤0.01% | 907 |
|
|
2019
Q1 | $3.59M | Buy |
8,746
+8,740
| +145,667% | +$3.6M | 0.01% | 645 |
|
|
2018
Q4 | $2K | Hold |
6
| – | – | ﹤0.01% | 1006 |
|
|
2018
Q3 | $2K | Sell |
6
-2
| -25% | -$761 | ﹤0.01% | 1036 |
|
|
2018
Q2 | $2K | Buy |
8
+4
| +100% | +$1.25K | ﹤0.01% | 1016 |
|
|
2018
Q1 | $1K | Hold |
4
| – | – | ﹤0.01% | 1029 |
|
|
2017
Q4 | $1K | Hold |
4
| – | – | ﹤0.01% | 1054 |
|
|
2017
Q3 | $1K | Hold |
4
| – | – | ﹤0.01% | 974 |
|
|
2017
Q2 | $1K | Hold |
4
| – | – | ﹤0.01% | 1000 |
|
|
2017
Q1 | $1K | Hold |
4
| – | – | ﹤0.01% | 1005 |
|
|
2016
Q4 | $1K | Hold |
4
| – | – | ﹤0.01% | 984 |
|
|
2016
Q3 | $1K | Sell |
4
-2,716
| -100% | -$1.09M | ﹤0.01% | 978 |
|
|
2016
Q2 | $949K | Buy |
2,720
+2,716
| +67,900% | +$1.05M | ﹤0.01% | 692 |
|
|
2016
Q1 | $1K | Hold |
4
| – | – | ﹤0.01% | 1020 |
|
|
2015
Q4 | $2K | Buy |
+4
| New | +$2.17K | ﹤0.01% | 1067 |
|
|
2014
Q4 | – | Sell |
-327
| Closed | -$117K | – | 1160 |
|
|
2014
Q3 | $117K | Buy |
+327
| New | +$110K | ﹤0.01% | 869 |
|
Other funds holding REGN
VCM
N
Lazard Asset Management's REGN Position: Q1 2026 in Review
Lazard Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 57% in Q1 2026, buying an estimated $4.72M and bringing the position to 17,004 shares worth $13.1M. The position accounts for 0.02% of the portfolio, ranked #390.
Lazard Asset Management first reported a position in REGN in Q3 2014 and has held it in 43 quarters since. The position peaked at $17.3M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Lazard Asset Management held 17,004 shares of Regeneron Pharmaceuticals worth $13.1M as of Q1 2026.
- Lazard Asset Management bought 6,166 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $4.72M.
- Regeneron Pharmaceuticals made up 0.02% of Lazard Asset Management's portfolio in Q1 2026, its #390 holding.
- Lazard Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2014 and has held it in 43 quarters since.
- Lazard Asset Management's Regeneron Pharmaceuticals position peaked at $17.3M in Q2 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.